USPTO serial 79332314
LIVITECH
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 25, 2023
- Examiner
- MCGILL, CIERRA L
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with LIVITECH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ronald M. Kachmarik
Ronald M. Kachmarik Cooper Legal Group, LLC1388 Ridge Road, Unit 1Hinckley, OH 44233UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents for chemical analyses for scientific use; reagents for scientific use; reagents for scientific or medical research use; diagnostic reagents for scientific use; reagents for immunoserology and molecular diagnosis for research use; chemical reagents for genetic research; in-vivo diagnostic reagents for scientific use; diagnostic reagents for scientific use or for research use; diagnostic reagents for in-vitro use in biochemistry, molecular biology, clinical chemistry and microbiology for research use; all these goods exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the public | ACTIVE | — |
| 005 | Pharmaceuticals for use in human or veterinary medicine, for scientific use for the treatment of inflammatory diseases and liver diseases; chemical preparations for use in human or veterinary medicine, or for pharmaceutical use, namely, for the treatment of inflammatory diseases and liver diseases; biological preparations for use in human or veterinary medicine, or for pharmaceutical use, namely, for the treatment of inflammatory diseases and liver diseases; preparations for use in human or veterinary medicine, or for pharmaceutical use, namely, for the treatment of inflammatory diseases and liver diseases; microorganism cultures for use in human or veterinary medicine, or for pharmaceutical use; cell preparations for use in human or veterinary medicine, or for pharmaceutical use, in particular for gene therapy and cell therapy, namely, cell growth media; blood and blood derived samples, namely plasma, serum, platelet free samples for medical use; diagnostic biomarker reagent products for use in human or veterinary medicine; diagnostic reagents for use in human or veterinary medicine; all these goods exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the public | ACTIVE | — |
| 009 | Downloadable software for use in diagnosis of inflammatory diseases and liver diseases; downloadable software applications for use in diagnosing medical conditions; scientific apparatus and instruments especially for recording, processing, reproducing, transmitting data, namely, electronic data loggers and recorders; data processing equipment; all these goods exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the public | ACTIVE | — |
| 010 | Medical apparatus, instruments and equipment, namely, DNA, RNA and protein analysis apparatus, DNA, RNA and protein quantifiers, medical devices for measuring DNA, RNA, biochemical and physical parameters, namely concentration of biomarkers relating to the evaluation of inflammatory and liver diseases and blood analyzers for evaluation of inflammatory and liver diseases; instruments and tools for medical diagnosis, namely, computer displays and computer monitors and controllers therefor used in direct association with medical diagnosis apparatus during the process of diagnosis of a condition in an individual; diagnostic apparatus for medical use, namely, medical diagnostic apparatus for testing the biomarker levels; all these goods exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the public | ACTIVE | — |
| 042 | Pharmaceutical research, namely, research for the discovery of new medicines; scientific research, especially in the medical, biomedical, chemical, genetic, pharmaceutical field; basic and applied scientific research; technical scientific research; scientific research, namely, sorting and selection of molecules; scientific research services, namely, development and validation of biological tests, cellular tests and genetic tests; scientific research, namely, functional genomics for identifying, characterizing, validating and developing biologically active molecules; analysis of biological substances in biological fluids; computer programming in the field of scientific research and for the pharmaceutical industry; engineering services, namely, surveying; technical project study being scientific research; professional consultancy unrelated to business dealings in the field of scientific and medical research; research and development of new pharmaceutical products for others; scientific research in the field of pharmacy; all these services exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the public | ACTIVE | — |
| 044 | Medical analysis relating to the diagnosis and treatment of persons and medical diagnosis services in inflammatory diseases and liver diseases; medical analyses of blood samples, biological preparations and biological fluids relating to the diagnosis and treatment of persons; support services in the field of medicine, health care and pharmaceutical research, namely, medical analysis for the diagnosis and treatment of patients; medical information; provision of medical information; all these services exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the public | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by GENFIT
- Other trademarks owned by GENFIT
- Other trademarks owned by GENFIT
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named LIVITECH
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 19, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 21, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 26, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 25, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 25, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 25, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jul 25, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 25, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 5, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 5, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| May 10, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| May 9, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 9, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 19, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 19, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 19, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 3, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 30, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 29, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 29, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 29, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 1, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 1, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 1, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 26, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 25, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 25, 2023 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jan 17, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 2, 2023 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 2, 2023 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 2, 2023 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 27, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 27, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 24, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 24, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 24, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 25, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 29, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 29, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 18, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 17, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 17, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 8, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 4, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 3, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |